NAFLD in Lean Asians.
作者信息
Eslam Mohammed, Chen Fei, George Jacob
机构信息
Storr Liver Centre Westmead Institute for Medical Research Westmead Hospital and University of Sydney Westmead New South Wales Australia.
出版信息
Clin Liver Dis (Hoboken). 2021 Jan 13;16(6):240-243. doi: 10.1002/cld.930. eCollection 2020 Dec.
Abstract
摘要
相似文献
1
NAFLD in Lean Asians.瘦亚洲人的非酒精性脂肪性肝病
Clin Liver Dis (Hoboken). 2021 Jan 13;16(6):240-243. doi: 10.1002/cld.930. eCollection 2020 Dec.
2
Lean NAFLD: An Underrecognized Outlier.瘦型非酒精性脂肪性肝病：一种未被充分认识的异常情况。
Curr Hepatol Rep. 2016 Jun;15(2):134-139. doi: 10.1007/s11901-016-0302-1. Epub 2016 Apr 14.
3
Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications.瘦人非酒精性脂肪性肝病：特征与影响
J Clin Transl Hepatol. 2017 Sep 28;5(3):216-223. doi: 10.14218/JCTH.2016.00068. Epub 2017 Jul 5.
4
Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study.非酒精性脂肪性肝病瘦患者发生严重肝病的风险：一项长期随访研究。
Hepatol Commun. 2017 Nov 30;2(1):48-57. doi: 10.1002/hep4.1124. eCollection 2018 Jan.
5
Metabolic syndrome is not uncommon among lean non-alcoholic fatty liver disease patients as compared with those with obesity.与肥胖的非酒精性脂肪性肝病患者相比，代谢综合征在瘦的非酒精性脂肪性肝病患者中并不少见。
Indian J Gastroenterol. 2020 Feb;39(1):75-83. doi: 10.1007/s12664-020-01020-3. Epub 2020 Apr 20.
6
Lean non-alcoholic fatty liver disease patients had comparable total caloric, carbohydrate, protein, fat, iron, sleep duration and overtime work as obese non-alcoholic fatty liver disease patients.瘦非酒精性脂肪性肝病患者的总热量、碳水化合物、蛋白质、脂肪、铁、睡眠时间和加班时间与肥胖非酒精性脂肪性肝病患者相当。
J Gastroenterol Hepatol. 2019 Jan;34(1):256-262. doi: 10.1111/jgh.14360. Epub 2018 Jul 16.
7
Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease.系统评价与荟萃分析：非酒精性脂肪性肝病瘦型患者组织学疾病严重程度的意义。
Aliment Pharmacol Ther. 2018 Jan;47(1):16-25. doi: 10.1111/apt.14401. Epub 2017 Oct 30.
8
Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.瘦型非酒精性脂肪性肝病患者的肝脏和心血管损伤，及其与内脏肥胖的关系。
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045. Epub 2017 May 26.
9
Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients.系统评价与荟萃分析：非酒精性脂肪性肝病的危险因素表明，瘦型和肥胖型患者存在共同的代谢和心血管特征改变。
Aliment Pharmacol Ther. 2017 Jul;46(2):85-95. doi: 10.1111/apt.14112. Epub 2017 May 2.
引用本文的文献
1
The impact of parity on the risk of nonalcoholic fatty liver disease defined by hepatic steatosis index: A nationwide cohort study.经肝脏脂肪变性指数定义的胎次对非酒精性脂肪性肝病风险的影响：一项全国性队列研究。
Sci Rep. 2025 Jul 24;15(1):26972. doi: 10.1038/s41598-025-11976-x.
2
Effect of lean status on the mortality of patients with non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis.瘦素状态对非酒精性脂肪性肝病（NAFLD）患者死亡率的影响：一项系统评价和荟萃分析。
Pak J Med Sci. 2025 Jun;41(6):1845-1853. doi: 10.12669/pjms.41.6.12044.
3
Differential risk factors of fibrosis between lean and obese MAFLD.非酒精性脂肪性肝病（MAFLD）患者中，瘦型与肥胖型患者肝纤维化的差异风险因素。
Clin Exp Med. 2025 Jun 18;25(1):211. doi: 10.1007/s10238-025-01749-1.
4
Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena.非酒精性脂肪性肝病的发展：一种多因素致病现象。
Liver Res. 2022 May 19;6(2):72-83. doi: 10.1016/j.livres.2022.05.002. eCollection 2022 Jun.
5
Metabolic dysfunction-associated steatotic liver disease: A silent pandemic.代谢功能障碍相关脂肪性肝病：一场无声的大流行。
World J Hepatol. 2024 Apr 27;16(4):511-516. doi: 10.4254/wjh.v16.i4.511.
6
Gut microbiota in MAFLD: therapeutic and diagnostic implications.非酒精性脂肪性肝病中的肠道微生物群：治疗和诊断意义
Ther Adv Endocrinol Metab. 2024 Apr 15;15:20420188241242937. doi: 10.1177/20420188241242937. eCollection 2024.
7
Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches.探讨遗传变异在非酒精性脂肪性肝病中的作用：对疾病发病机制和精准医学方法的启示。
Eur J Med Res. 2024 Mar 20;29(1):190. doi: 10.1186/s40001-024-01708-8.
8
Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome.代谢综合征：肝纤维化和癌症的沉默威胁。
Diabetes Metab J. 2024 Mar;48(2):161-169. doi: 10.4093/dmj.2023.0240. Epub 2024 Jan 26.
9
What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside.瘦人代谢功能障碍相关脂肪性肝病的新进展：从 bench 到 bedside。
（注：“bench”和“bedside”在这里可能是比喻从基础研究到临床应用的过程，直译为“从实验台到病床边”，但这样表述稍显生硬，所以整体保留英文更符合语境。）
J Clin Med. 2024 Jan 3;13(1):278. doi: 10.3390/jcm13010278.
10
NAFLD and NAFLD-related HCC in Asia: Burden and Surveillance.亚洲的非酒精性脂肪性肝病及非酒精性脂肪性肝病相关肝细胞癌：负担与监测
J Clin Exp Hepatol. 2024 Jan-Feb;14(1):101213. doi: 10.1016/j.jceh.2023.06.013. Epub 2023 Jul 5.
本文引用的文献
1
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation.瘦型非酒精性脂肪性肝病：一种由不同代谢适应塑造的独特实体。
Hepatology. 2020 Apr;71(4):1213-1227. doi: 10.1002/hep.30908. Epub 2020 Jan 24.
2
Lean non-alcoholic fatty liver disease and development of diabetes: a cohort study.瘦型非酒精性脂肪性肝病与糖尿病的发生：队列研究。
Eur J Endocrinol. 2019 Aug;181(2):185-192. doi: 10.1530/EJE-19-0143.
3
Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease.生活方式干预对非肥胖非酒精性脂肪性肝病患者的有益影响。
J Hepatol. 2018 Dec;69(6):1349-1356. doi: 10.1016/j.jhep.2018.08.011. Epub 2018 Aug 22.
4
Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis.利拉鲁肽可减轻晚期瘦型非酒精性脂肪性肝炎的肝脏炎症和损伤。
Basic Clin Pharmacol Toxicol. 2018 Dec;123(6):704-713. doi: 10.1111/bcpt.13082. Epub 2018 Jul 30.
5
Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts.补充特级初榨橄榄油或坚果的地中海饮食对心血管疾病的一级预防
N Engl J Med. 2018 Jun 21;378(25):e34. doi: 10.1056/NEJMoa1800389. Epub 2018 Jun 13.
6
Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study.非酒精性脂肪性肝病瘦患者发生严重肝病的风险：一项长期随访研究。
Hepatol Commun. 2017 Nov 30;2(1):48-57. doi: 10.1002/hep4.1124. eCollection 2018 Jan.
7
Genetics and epigenetics of NAFLD and NASH: Clinical impact.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的遗传学和表观遗传学：临床影响。
J Hepatol. 2018 Feb;68(2):268-279. doi: 10.1016/j.jhep.2017.09.003. Epub 2017 Nov 6.
8
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的全球负担：趋势、预测、危险因素和预防。
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109. Epub 2017 Sep 20.
9
Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease.干扰素 lambda 4 rs368234815 TT>δG 变异与非酒精性脂肪性肝病患者的肝损伤有关。
Hepatology. 2017 Dec;66(6):1885-1893. doi: 10.1002/hep.29395. Epub 2017 Nov 6.
10
Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver.非酒精性脂肪肝的瘦白种人受试者的临床和代谢特征
Am J Gastroenterol. 2017 Jan;112(1):102-110. doi: 10.1038/ajg.2016.318. Epub 2016 Aug 16.
Zotero 插件